These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 33973347)

  • 1. Alemtuzumab-induced Alopecia areata - a case report and systematic literature review of adverse events associated with Alemtuzumab.
    Dikeoulia E; Neufeld M; Pawlitzki M; Böhm M
    J Dtsch Dermatol Ges; 2021 Aug; 19(8):1159-1163. PubMed ID: 33973347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case of alemtuzumab-related alopecia areata management in MS.
    Chan JK; Traboulsee AL; Sayao AL
    Neurol Neuroimmunol Neuroinflamm; 2019 Jan; 6(1):e516. PubMed ID: 30568994
    [No Abstract]   [Full Text] [Related]  

  • 3. Recurrent and universal alopecia areata following alemtuzumab treatment in multiple sclerosis: A secondary autoimmune disease.
    Alcalá C; Pzére-Miralles F; Gascón F; Evole M; Estutia M; Gil-Perotín S; Casanova B
    Mult Scler Relat Disord; 2019 Jan; 27():406-408. PubMed ID: 30530069
    [No Abstract]   [Full Text] [Related]  

  • 4. Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).
    Vukusic S; Brassat D; de Seze J; Izquierdo G; Lysandropoulos A; Moll W; Vanopdenbosch L; Arque MJ; Kertous M; Rufi P; Oreja-Guevara C
    Mult Scler Relat Disord; 2019 Apr; 29():7-14. PubMed ID: 30654246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells.
    Ruck T; Pfeuffer S; Schulte-Mecklenbeck A; Gross CC; Lindner M; Metze D; Ehrchen J; Sondermann W; Pul R; Kleinschnitz C; Wiendl H; Meuth SG; Klotz L
    Neurology; 2018 Dec; 91(24):e2233-e2237. PubMed ID: 30404783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early neutropenia with thrombocytopenia following alemtuzumab treatment for multiple sclerosis: case report and review of literature.
    Maniscalco GT; Cerillo I; Servillo G; Napolitano M; Guarcello G; Abate V; Improta G; Florio C
    Clin Neurol Neurosurg; 2018 Dec; 175():134-136. PubMed ID: 30419425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alopecia Universalis following Alemtuzumab Treatment in Multiple Sclerosis: A Barely Recognized Manifestation of Secondary Autoimmunity-Report of a Case and Review of the Literature.
    Zimmermann J; Buhl T; Müller M
    Front Neurol; 2017; 8():569. PubMed ID: 29163335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report.
    Lapucci C; Gualandi F; Mikulska M; Palmeri S; Mancardi G; Uccelli A; Laroni A
    Mult Scler Relat Disord; 2018 Nov; 26():52-54. PubMed ID: 30223229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diffuse alveolar hemorrhage as an early complication of alemtuzumab treatment: A case report of a multiple sclerosis patient and an overview of 14 cases.
    Drop BRH; Zemel D; Wokke BHA; van Oosten BW; Dik S; Martins Jarnalo CO; Westerweel PE; de Beukelaar JWK
    Mult Scler Relat Disord; 2021 Jan; 47():102614. PubMed ID: 33249378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Vitiligo with Koebner phenomenon in a patient with multiple sclerosis treated with alemtuzumab].
    Eichau S; Lopez-Ruiz R; Ruiz-Pena JL; Paramo MD; Navarro-Mascarell G; Izquierdo G
    Rev Neurol; 2018 Jun; 66(11):395-396. PubMed ID: 29790573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis.
    Romba MC; Newsome SD; McArthur JC
    Mult Scler Relat Disord; 2019 Sep; 34():100-102. PubMed ID: 31252364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ANCA-associated life-threatening systemic vasculitis after alemtuzumab treatment for multiple sclerosis.
    Horisberger A; Pantazou V; Cuendet G; Ribi C; Dunet V; Théaudin M
    Mult Scler; 2020 Oct; 26(12):1599-1602. PubMed ID: 32081100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemophagocytic syndrome following alemtuzumab treatment for multiple sclerosis: A case report.
    Romero A; Midaglia L; Salcedo MT; Viladomiu L; Guillén E; Bajaña I; Escolà-Vergé L; Tintoré M; Montalban X; Len O
    Mult Scler Relat Disord; 2020 May; 40():101973. PubMed ID: 32028116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis.
    Iovino A; Aruta F; Carotenuto A; Manganelli F; Iodice R
    Mult Scler Relat Disord; 2019 Feb; 28():98-100. PubMed ID: 30580038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alemtuzumab for relapsing multiple sclerosis in clinical practice: A four-year retrospective one-center study.
    Rodríguez de Castro B; Pampín Sánchez R; Tembrás Martinez S; Ayastuy Ruiz A; Martínez-Múgica Barbosa C
    Int J Risk Saf Med; 2020; 31(4):259-265. PubMed ID: 32145001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alopecia Universalis Occurring after Alemtuzumab Treatment for Multiple Sclerosis. A Two-Year Follow-Up of Two Patients.
    Borriello G; Ianniello A; Toosy AT
    Int J Environ Res Public Health; 2021 Jul; 18(14):. PubMed ID: 34299789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pneumonitis secondary to alemtuzumab in a patient with multiple sclerosis - A non-infectious cause of breathlessness.
    Whiteside D; Barth S; Datta A; Trip SA
    Mult Scler Relat Disord; 2018 May; 22():139-140. PubMed ID: 29684788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An unforeseen reality: Hemophagocytic lymphohistiocytosis following alemtuzumab treatment for a multiple sclerosis.
    Ošep AB; Brecl E; Škerget M; Savšek L
    Clin Neurol Neurosurg; 2023 May; 228():107675. PubMed ID: 36965418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary embolism during the third cycle of alemtuzumab in a patient with relapsing multiple sclerosis.
    Habek M; Ruška B; Pavičić T; Alduk AM; Gabelić T; Adamec I
    Mult Scler Relat Disord; 2019 Oct; 35():5-6. PubMed ID: 31276912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
    Hettle R; Harty G; Wong SL
    J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.